Founder & CEO (PreSeed Health tech) - Cognitive Decline Early Detection Platform

Founders Factory builds and funds startups together with exceptional entrepreneurs and the world's leading companies. Created by IPO-exited founders, we offer founders capital, operational support from a team of hands-on experts, and unrivalled access to a coalition of industry-leading corporate partners. Since 2015, Founders Factory’s 450+ portfolio companies have secured 500+ pilots and commercial contracts with our partners.

Our Studio partners with entrepreneurs at day one, developing new ideas, technologies and business models into high-growth companies. In partnership with a leading global industrial healthcare partner, we are building a new portfolio of healthcare ventures.

About The Venture

Over 55 million people worldwide live with dementia, and the number is projected to triple by 2050. In the US alone, Alzheimer's and related dementias cost $345 billion annually in direct care — and by the time most patients receive a diagnosis, years of irreversible decline have already occurred.

The clinical consensus is clear: earlier detection transforms outcomes. Emerging treatments like lecanemab (Leqembi) and donanemab work best — or only — in early-stage disease. But today's diagnostic pathway is reactive: a patient or family member notices something wrong, waits months for a specialist, and undergoes episodic cognitive testing that captures a snapshot, not a trajectory.

We are building a continuous, ambient home monitoring platform that detects the earliest behavioural and physiological signals of cognitive and neurological decline — before the patient or family notices. Using our partner’s industrial-grade radar sensors (60GHz, ceiling-mounted, no cameras, no wearables), the system builds a behavioural baseline for each individual: gait patterns, sleep architecture, daily activity rhythms, bathroom frequency. When subtle but clinically meaningful changes emerge — shorter stride, more night-time awakenings, reduced activity range — the platform flags them to the care team and family, enabling intervention months or years earlier than current practice.

The initial wedge is the US market, where the convergence of FDA-cleared digital therapeutics, Medicare reimbursement pathways for remote patient monitoring, and the arrival of disease-modifying treatments creates unprecedented commercial pull for early-detection infrastructure. The remote patient monitoring market is $27.7B globally (2024), projected to reach $57–88B by 2030.

Beyond detection, the platform becomes the caregiver's operating system: contextualised alerts, care coordination, family reporting, and a longitudinal dataset that compounds with every patient monitored — the evidence base that clinicians, payers, and pharma companies need.

Our Offer

We don't just fund ideas — we co-build them. Join as Founder & CEO and get access to a full-stack venture studio offering designed to give you the best possible start:

• €275k of spin out capital plus a founder stipend + studio budget to build, validate, and launch
• Expert Team: Hands-on support across product, growth, fundraising, AI/ML, design, legal, hiring, and more
• MVP Build: Full-time venture builder(s) to help ship your first product
• Accelerator: 6 months of deep operational support post-launch
• Strategic Network: Intros to top-tier investors and corporate partners
• Validation: A vetted concept, domain insight, and a head start in a massive market
  
  

Jobs to be Done

As Founder & CEO, you will be responsible for turning a strong thesis into a scaled, defensible business.

• Define the clinical wedge. Decide which population and care setting you target first: memory care communities, post-diagnosis home monitoring, high-risk screening cohorts, or clinical trial enrichment for pharma.
• Turn ambient data into clinical intelligence. Build the algorithms that distinguish normal ageing variation from clinically meaningful decline — and deliver actionable alerts, not noise.
• Win the first customer. Secure a lighthouse partner — whether a senior living operator, a health system neurology department, a pharma company running AD trials, or a Medicare Advantage plan.
• Navigate the regulatory path. Determine the right FDA positioning (wellness vs. Class II device) and build the evidence package to support it.
• Build the caregiver layer. Design the family-facing experience that turns continuous monitoring into peace of mind — not anxiety.
• Build the company. Hire the initial team, raise capital, and establish the venture as the category leader for ambient neurological monitoring.
  
  

Your Ideal Experience

We are not looking for a traditional healthcare executive or a pure AI researcher. The ideal candidate sits at the intersection.

• Founder or senior operator who has built a health-tech, med-tech, or digital health product from zero to one in the US market.
• Deep familiarity with the US healthcare ecosystem: Medicare reimbursement, FDA regulatory pathways, health system procurement, or pharma partnerships.
• Strong product and technical instincts: you can reason about sensor data, ML pipelines, clinical validation, and care delivery models.
• Experience selling to complex healthcare buyers: health systems, senior living operators, payers, or pharma.
• Comfortable operating in ambiguity: shaping the product, defining the clinical use case, and making calls at the intersection of technology, regulation, and clinical science.
• Passion for ageing, neuroscience, or caregiver support — ideally with personal or professional proximity to the problem.
  
  

Most importantly, you are motivated by building the platform that catches decline early enough to change its course — and gives families the information they need, when they need it.